Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Recent studies have showed that 5-methylcytosine (m5C) can be utilized to assess the prognosis of tumors. However, the role of clinical implications of m5C modification remains unclear. The mRNA expression profiles and clinical features were downed from GEO and ICGC databases.In order to screen out m5C regulators,Univariate and multivariate Cox regression were performed. The survival rate was determined using K-M survival analysis. Then the risk model was validated in ICGC and GSE63156 two external datasets. A nomogram was created using risk level and clinical features, well validated by calibration curve. ESTIMATE, MCP-counter and GSVA algorithms were applied to assess tumor microenvironment, immune cell, and immune function. Several drugs exhibited sensitivity for potential therapy of ES. Five m5C regulators (YBX1, TET2, NOP2, DNMT3A, DNMT1) were screened out as risk signatures. The Kaplan-Meier survival analysis demonstrated that the high-risk group had a lower survival rate compared to the low-risk group(p = 0.0026). The AUC of ROC curves in 1, 3, 5 years ranged from 0.752 to 0.829. Based on the amount of risk and clinical characteristics, a nomogram was created and well validated by calibration curve.ESTIMATE, MCP-counter and GSVA algorithms were applied to assess tumor mircoenvironment, immune cell, and immune function. Several drugs exhibited sensitivity for potential therapy of ES. The present research indicated that m5C regulators (YBX1, TET2, NOP2, DNMT3A, DNMT1) play critical roles in ES progression, and provide new insight in ES prognosis prediction.